The Study
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.
This study is like a fair test where people were randomly given either a special medicine, a diet, or another pill, and scientists watched what happened to their blood sugar. Because they switched some people to a blocker to see if the medicine stopped working, they can say the medicine itself caused the improvement—not just losing weight.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Liraglutide is a drug that turns on a specific receptor in your body, which helps your body use insulin better and lowers blood sugar—even before you lose any weight.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 589 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes—this means people with prediabetes can get metabolic benefits from liraglutide quickly, even if they haven’t lost weight yet.
- 2After 2 weeks, liraglutide lowered blood sugar and improved insulin sensitivity by 20-30% (HOMA-IR, Matsuda index), while diet and sitagliptin did not.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2023
Authors
M. Mashayekhi, Hui Nian, Dustin Mayfield, Jessica K Devin, Jorge L. Gamboa, Chang Yu, Heidi J Silver, K. Niswender, James M. Luther, Nancy J. Brown
Related Content
Claims (10)
GLP-1 receptor agonists trigger changes in the body that occur even when weight loss is accounted for, suggesting these drugs have effects beyond reducing body weight.
Liraglutide increases insulin sensitivity and lowers blood glucose levels after fasting and after meals in people with obesity and prediabetes by activating GLP-1 receptors, without requiring weight loss and differently from how DPP-4 inhibitors or dieting affect glucose.
Liraglutide enhances insulin sensitivity and glucose control in people with obesity and prediabetes by acting through a biological pathway that is different from weight loss or the body's natural incretin system, as shown by blocking GLP-1 receptors reversing the effect and sitagliptin having no effect.
In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after fasting and after meals within two weeks, even without weight loss. This effect is not seen with other approaches that increase GLP-1 naturally or reduce calories, suggesting liraglutide works through a distinct mechanism.
In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after eating and in the fasted state within two weeks, even without weight loss, and these effects are not seen with other approaches like sitagliptin or dieting alone.
In people with obesity and prediabetes, a daily dose of liraglutide improves how the body responds to insulin within two weeks, before any significant weight loss occurs, and this improvement is blocked when the GLP-1 receptor is inhibited.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.